Cargando…

Impact of rituximab on humoral response to SARS-CoV-2 vaccination in previously vaccinated patients with autoimmune diseases

SARS-CoV-2 infection is more severe in patients undergoing rituximab (RTX) treatment. Humoral response to vaccination is severely impaired in patients already treated with RTX, but data on antibody persistence in patients initiating RTX are lacking. We evaluated the impact of RTX initiation on humor...

Descripción completa

Detalles Bibliográficos
Autores principales: Oliosi, E., Flahault, A., Charre, C., Veyer, D., Combier, A., Lafont, E., Karras, A., Mouthon, L., Avouac, J., Terrier, B., Hadjadj, J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10224652/
https://www.ncbi.nlm.nih.gov/pubmed/37243801
http://dx.doi.org/10.1007/s10067-023-06638-0